Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Neurosci Res ; 95(5): 1182-1193, 2017 05.
Article in English | MEDLINE | ID: mdl-27898171

ABSTRACT

Abnormal redox homeostasis and oxidative stress have been proposed to play a role in the etiology of several neuropsychiatric spectrum disorders. Emerging interest has recently focused on markers of oxidative stress and neuroinflammation in schizophrenic spectrum disorders, at least in particular subgroups of patients. Altered expression of genes related to oxidative stress, oxidative damage to DNA, protein and lipids, as well as reduced glutathione levels in central and peripheral tissues could act synergistically, and contribute to the course of the disease. Herein, we discuss cellular mechanisms that may be operative in neuroinflammation and contributory to schizophrenia. We address modulation of endogenous cellular defense mechanisms as a potentially innovative approach to therapeutics for schizophrenia, and other neuropsychiatric conditions that are associated with neuroinflammation. Specifically, we discuss the emerging role of heme oxygenase as prominent member of neuroprotective network in redox stress responsive mechanisms, as well as the importance of glutathione relevant in schizophrenia pathophysiology. Finally we introduce the hormetic dose response concept as relevant and important to neuroprotection, and review hormetic mechanisms as possible approaches to manipulation of neuroinflammatory targets that may be viable for treating schizophrenia spectrum disorders. © 2016 Wiley Periodicals, Inc.


Subject(s)
Encephalitis/etiology , Hormesis , Schizophrenia/complications , Animals , Encephalitis/drug therapy , Heat-Shock Response , Heme Oxygenase (Decyclizing)/metabolism , Hormesis/drug effects , Hormesis/physiology , Humans , Mitochondrial Diseases/etiology , Neuroprotective Agents/therapeutic use
2.
Res Dev Disabil ; 34(9): 2543-50, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23751299

ABSTRACT

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common diagnosis for children and adolescents, although the reported estimates for prevalence are extremely variable worldwide. In the present work we investigate the prevalence of ADHD in a sample of Italian students in a study divided in two phases. In Phase I, a total of 6183 schoolchildren (3178 males and 3005 females, aged range 5-15 years) were screened using the SDAI rating scale for teachers. In Phase II, the parents of children and adolescents who met high screen criteria according to SDAI (cut-off>14; n=471, 7.3%) were invited to complete a specific clinical-diagnostic assessment for ADHD with the help of an experienced clinician. Within the entire sample, 107 children dropped out and 12 had mental retardation, whereas 332 subjects (278 males and 54 females, age range 5-14 years) completed the Phase II of the study. One hundred ninety subjects (163 males and 27 females, male: female ratio 6:1, mean age 8 years) were diagnosed with ADHD, indicating a prevalence of 3%. ADHD subtypes included the following: combined (n=108; 56.8%), inattentive (n=48; 25.2%) and hyperactive/impulsive (n=33; 17.3%). Our findings are in line with other reports of ADHD prevalence in the European Countries, and may contribute to underline the impact of this phenomenon in the population, and the need of achieving an improvement in the quality of the public health mental service for the prevention and treatment of ADHD.


Subject(s)
Attention Deficit Disorder with Hyperactivity/diagnosis , Attention Deficit Disorder with Hyperactivity/epidemiology , Mass Screening , Students/statistics & numerical data , Adolescent , Child , Child, Preschool , Faculty , Female , Humans , Italy/epidemiology , Male , Parents , Prevalence , Severity of Illness Index
3.
Pediatr Neurol ; 30(2): 107-10, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14984902

ABSTRACT

The objective of this study was to assess brain involvement through the presence of antineuronal antibodies in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus (PANDAS) and in uncomplicated active Group A streptococcal infection. We compared serum antibrain antibody to human basal ganglia sections assessed by indirect tissue immunofluorescence in two groups: a PANDAS group, comprised of 22 patients (mean age 10.1 years; 20 male, 2 female) who met strict National Institutes of Mental Health diagnostic criteria for PANDAS and had clinically active tics or obsessive-compulsive disorder, or both; and a GABHS control group consisting of 22 patients (mean age 9.1 years; 15 mol/L, 7 female) with clinical evidence of active Group A beta-hemolytic streptococcal (GABHS) infection confirmed by throat culture and elevated antistreptolysin O titers but without history or clinical evidence of tics or obsessive-compulsive disorder. We observed positive anti-basal ganglia staining (defined as detectable staining at 1:10 serum dilution) in 14/22 patients in the PANDAS group (64%) but only 2/22 (9%) in the GABHS control group (P < 0.001, Fisher's exact test). These results suggest that antibrain antibodies are present in children with PANDAS that cannot be explained merely by a history of GABHS infection.


Subject(s)
Antibody Formation , Brain/immunology , Mental Disorders/immunology , Streptococcal Infections/immunology , Streptococcus agalactiae/immunology , Adolescent , Antistreptolysin/biosynthesis , Brain/metabolism , Child , Deoxyribonucleases/immunology , Female , Humans , Male , Mental Disorders/complications , Mental Disorders/enzymology , Neurons/immunology , Streptococcal Infections/complications , Streptococcal Infections/enzymology
4.
J Child Neurol ; 18(1): 79-81, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12661947

ABSTRACT

A 2-year-old girl presented with severe global developmental delay weakness, and an elevated serum creatine kinase level. Her muscle biopsy was consistent with an active dystrophy with absence of dystrophin in about half of the muscle fibers. Fluorescent in situ hybridization analysis showed her karyotype to be 46, X, delX p23.1-p21.1. This large deletion includes the dystrophin gene as well as the region involved in X-linked mental retardation. The genetic mechanism for the manifestation of both diseases is likely non-random inactivation of the X chromosome. To our knowledge, the combination of this dystrophinopathy in association with severe mental retardation has not been described in a girl.


Subject(s)
Chromosome Deletion , Chromosomes, Human, X , Creatine Kinase/blood , Mental Retardation, X-Linked/genetics , Muscular Dystrophies/genetics , Sex Chromosome Aberrations , Child, Preschool , DNA Mutational Analysis , Dystrophin/genetics , Female , Germ-Line Mutation/genetics , Humans , Mental Retardation, X-Linked/diagnosis , Muscular Dystrophies/diagnosis , Neurologic Examination
SELECTION OF CITATIONS
SEARCH DETAIL
...